The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 533 KB) and Technical Notes (PDF, 752 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 1.22

U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2011a Using Different Tumor Inclusion Criteriab
Site Sex 5-Year Limited Duration Prevalence 36-year Limited Duration Prevalence
1st Invasive
Tumor Everc		 1st Per Site in
Previous 36 Yearsd		 1st Per Site in
Previous 5 Yearse		 1st Invasive
Tumor Everc		 1st Per Site in
Previous 36 Yearsd
All Sites Both Sexes 4,594,732 4,684,591 5,152,908 12,998,655 13,213,910
Male 2,373,342 2,409,199 2,638,979 6,188,275 6,261,129
Female 2,221,390 2,275,392 2,513,929 6,810,380 6,952,781
Oral Cavity & Pharynx Both Sexes 104,979 121,403 125,889 272,072 300,609
Male 73,503 84,311 87,116 181,087 198,337
Female 31,476 37,092 38,773 90,985 102,272
Esophagus Both Sexes 21,165 26,055 26,172 34,428 40,593
Male 16,662 20,345 20,416 26,846 31,461
Female 4,503 5,710 5,756 7,582 9,132
Stomach Both Sexes 36,380 43,398 43,779 72,734 83,348
Male 21,307 26,023 26,197 41,394 47,992
Female 15,073 17,375 17,582 31,340 35,356
Colon & Rectum Both Sexes 403,434 465,899 475,547 1,140,625 1,270,460
Male 206,233 237,736 242,463 567,872 629,107
Female 197,201 228,163 233,084 572,753 641,353
Liver & Intrahepatic Bile Duct Both Sexes 33,682 38,427 38,461 45,468 50,961
Male 24,703 27,797 27,819 32,312 35,854
Female 8,979 10,630 10,642 13,156 15,107
Pancreas Both Sexes 32,756 39,642 39,654 43,238 51,264
Male 16,110 19,950 19,962 20,679 25,032
Female 16,646 19,692 19,692 22,559 26,232
Larynx Both Sexes 31,318 37,292 37,636 87,652 98,482
Male 25,568 30,391 30,700 70,687 79,142
Female 5,750 6,901 6,936 16,965 19,340
Lung & Bronchus Both Sexes 231,126 297,286 306,343 395,186 487,438
Male 107,276 140,106 143,631 179,129 222,121
Female 123,850 157,180 162,712 216,057 265,317
Melanoma of the Skin Both Sexes 282,028 320,618 335,149 924,397 998,829
Male 151,313 176,523 185,633 459,686 503,903
Female 130,715 144,095 149,516 464,711 494,926
Breast Female 855,411 924,344 982,776 2,847,146 3,016,451
Cervix Female 39,578 41,703 41,825 211,309 217,336
Corpus & Uterus, NOS Female 177,109 198,883 199,045 584,180 637,931
Ovaryf Female 58,762 67,726 67,789 173,192 194,691
Prostate Male 1,047,674 1,131,608 1,131,634 2,706,583 2,883,365
Testis Male 42,114 42,942 43,546 212,079 214,995
Urinary Bladder Both Sexes 200,849 251,314 256,779 560,445 653,826
Male 152,753 192,335 196,676 418,562 489,001
Female 48,096 58,979 60,103 141,883 164,825
Kidney & Renal Pelvis Both Sexes 149,969 182,913 185,010 347,916 406,298
Male 91,313 113,044 114,471 206,735 243,752
Female 58,656 69,869 70,539 141,181 162,546
Brain & Nervous System Both Sexes 44,217 47,403 47,827 131,408 135,930
Male 24,099 25,776 26,028 69,809 72,101
Female 20,118 21,627 21,799 61,599 63,829
Thyroid Both Sexes 174,786 194,868 195,449 527,919 564,773
Male 38,665 45,067 45,197 114,267 125,269
Female 136,121 149,801 150,252 413,652 439,504
Hodgkin Lymphoma Both Sexes 38,529 41,043 41,065 172,689 177,526
Male 20,912 22,396 22,407 89,550 92,081
Female 17,617 18,647 18,658 83,139 85,445
Non-Hodgkin Lymphoma Both Sexes 203,992 239,804 242,418 522,113 584,133
Male 109,031 129,460 130,668 274,206 307,672
Female 94,961 110,344 111,750 247,907 276,461
Myeloma Both Sexes 52,505 62,629 62,743 83,118 95,874
Male 28,573 34,693 34,761 45,299 52,835
Female 23,932 27,936 27,982 37,819 43,039
Leukemia Both Sexes 115,823 134,637 135,040 297,129 327,520
Male 66,545 78,337 78,566 168,443 186,907
Female 49,278 56,300 56,474 128,686 140,613
Acute Lymphocytic Leukemia Both Sexes 16,260 16,720 16,720 68,728 69,433
Male 9,051 9,286 9,286 37,729 38,032
Female 7,209 7,434 7,434 30,999 31,401
Childhood (Ages 0-19) Both Sexes 63,918 63,993 64,508 314,920 315,399
Male 33,711 33,746 33,991 162,108 162,335
Female 30,207 30,247 30,517 152,812 153,064
Kaposi Sarcoma Both Sexes 7,194 7,680 7,680 25,504 26,815
Male 6,655 7,078 7,078 24,134 25,255
Female 539 602 602 1,370 1,560
Mesothelioma Both Sexes 3,004 3,922 3,922 4,663 5,734
Male 2,172 2,854 2,854 2,829 3,595
Female 832 1,068 1,068 1,834 2,139

Footnotes:

a U.S. 2011 cancer prevalence counts are based on 2011 cancer prevalence proportions from the SEER 9 registries and 1/1/2011 U.S. population estimates based on the average of 2010 and 2011 population estimates from the U.S. Bureau of the Census.

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion which are listed in footnotes (c) to (e).

c First invasive tumor ever. Referred to as method (c) in Example below.

d First invasive tumor for each cancer site diagnosed during the previous 36 years (1975-2010). All sites is treated as a separate cancer "site". Referred to as method (d) in Example below.

e First invasive tumor for each cancer site diagnosed during the previous 5 years (2006-2010). All sites is treated as a separate cancer "site". Referred to as method (e) in Example below.

Example: Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2006; Melanoma in 2007.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 36-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2011.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 36-year limited duration prevalence. The 2006 breast cancer is counted for the breast 5-year and 36-year limited duration prevalence.
In method (e) the 2006 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2007 melanoma is counted for 5-year limited duration prevalence for melanoma.

f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.